WHWK

Whitehawk (ex-Aadi) is no longer the company its P/S implies. Management explicitly describes it as a 'preclinical-stage biopharmaceutical company' that 'had a single product approved for commercial sale that we have divested' — that divestiture is why FY2025 revenue collapsed 72.5% to $7.14M and why the headline P/S of 27.7x is meaningless. There is no commercial business here; value rests entirely on three in-licensed ADCs (HWK-007, HWK-016, HWK-206) built on WuXi Biologics/Hangzhou DAC's CPT113 linker-payload. Two INDs are cleared with Phase 1 trials recruiting, but the first data readouts are not expected until H1 2027 — meaning nothing de-risks the thesis for roughly 18 months.

The balance sheet looks superficially clean — liabilities/equity of just 0.11x, $136M equity, $149M current assets against only $14.5M current liabilities — but the burn tells the real story. Operating income was -$114M, operating cash flow -$97.4M (worsened 63.6% YoY as R&D jumped 78% to $91M), and stated cash is only $37.6M. Even crediting the ~$111M of implied marketable securities inside current assets, that is roughly 1.5 years of runway against a rising burn rate. The company states plainly it 'will require additional capital' and may be 'forced to delay, reduce and/or eliminate' programs if it cannot raise on acceptable terms — a financing overhang that will almost certainly hit before any Phase 1 data, and likely dilutively given a depressed $4.19 share price.